NH102 · program
NH102 for Major depressive disorder
NH102, Jiangsu Nhwa Pharmaceutical's oral serotonin-norepinephrine reuptake inhibitor with 5-HT2A antagonism, for major depressive disorder. After single- and multiple-ascending-dose Phase 1 studies in Chinese healthy volunteers (2021-2023), Nhwa ran a 243-patient, 22-site, randomized, double-blind, double-dummy Phase 2 dose-finding trial (NCT06842992) comparing NH102 10, 20 and 30 mg/day with placebo and duloxetine 60 mg over 6 weeks. Results presented at ECNP 2026: the 30 mg dose beat placebo on the primary HAMD-17 endpoint at week 6 (difference -2.8, P=0.036) and on MADRS, CGI-I and CGI-S; the 10 and 20 mg doses were not significantly different from placebo, and 30 mg was not significantly different from duloxetine. Tolerability was acceptable, with numerically less nausea and diarrhoea than duloxetine. Nhwa's 2026 interim report lists the Phase 2 as completed; no Phase 3 has been registered or announced.
Development timeline
- metPhase 2 proof-of-concept in MDD: NH102 30 mg beat placebo on HAMD-17 at week 6 (difference -2.8, P=0.036); lower doses not significant; not different from duloxetine.↗
- NCT06842992 completed (primary completion 2025-07-30, study completion 2025-09-12). Nhwa's 2026 interim report lists NH102 tablet among projects that have completed Phase II.
- Phase 2 dose-finding trial NCT06842992 (NH102-21) in major depressive disorder started; 243 enrolled.
Readouts
- 2026-10-11ReportedFull resultsmetNCT06842992
Phase 2 proof-of-concept in MDD: NH102 30 mg beat placebo on HAMD-17 at week 6 (difference -2.8, P=0.036); lower doses not significant; not different from duloxetine. ↗
Clinical trials in Major depressive disorder
NCT06842992NH102-21Phase 2Completedn=243
A Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Dose-exploration Phase II Clinical Trial to Evaluate the Efficacy and Safety of NH102 in the Treatment of Depression
metsecondaryChange from baseline in MADRS total score (key secondary), NH102 30 mg vs placebo (0.0045)
NH102 30 mg significantly improved MADRS vs placebo; CGI-I (P=0.004) and CGI-S (P=0.008) also improved. Mostly mild-to-moderate adverse events; numerically fewer gastrointestinal events (nausea, diarrhoea) than duloxetine.
metprimaryChange from baseline in HAMD-17 total score at week 6, NH102 30 mg vs placebo — LSM difference -2.8 (95% CI -5.4 to -0.2) (0.036)
NH102 30 mg/day beat placebo on HAMD-17 at week 6. The 10 mg and 20 mg doses were numerically better than placebo but not significant. NH102 30 mg vs duloxetine 60 mg: LSM difference -0.3, P=0.79 (not significant).
NCT07324408NH102-12Phase 1Completedn=40
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiply Ascending Dose of NH102 in Healthy Subjects
NCT05015192NH102-11Phase 1Completedn=55
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Single Ascending Dose of NH102 in Healthy Subjects
Formulations
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| NH102 oral tablet (twice daily) Phase 2 (NCT06842992): 5 mg, 10 mg or 15 mg twice daily (10/20/30 mg/day) for 6 weeks, then a 1-week taper. Phase 1 SAD (NCT05015192): single oral tablet doses 3-80 mg fasted. Phase 1 MAD (NCT07324408): 3 mg and 10 mg BID, plus titrations to 15 mg and 20 mg BID. | Oral | Twice daily | — |
Mechanism of action
Described by the Phase 2 investigators as a novel multimodal antidepressant combining potent serotonin and norepinephrine reuptake inhibition with moderate serotonin 5-HT2A receptor antagonism, a profile they propose may preserve antidepressant efficacy while improving tolerability. No binding or functional potency data, and no chemical structure, have been publicly disclosed.
| Target | Action | Affinity |
|---|---|---|
| SERTprimarySLC6A4 | Reuptake inhibitor | —ⓘ |
| 5-HT2AHTR2A | Antagonist | —ⓘ |
| NETSLC6A2 | Reuptake inhibitor | —ⓘ |
← Full NH102 compound page (identity, identifiers, all indications)
Sources
- Efficacy and safety of NH102 in major depressive disorder: a randomised, phase 2 proof-of-concept clinical trial (ECNP 2026, PS02-2113) — ECNP Congress 2026 (reproduced on cnspulse.com)
- NCT05015192 (NH102-11) - Single Ascending Dose Study of NH102 in Healthy Subjects — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT06842992 (NH102-21) - A Phase II Study to Evaluate NH102 for Depression — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT07324408 (NH102-12) - Multiple Ascending Dose Study of NH102 in Healthy Subjects — ClinicalTrials.gov (U.S. National Library of Medicine)